Latest & greatest articles for type 1 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 1 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 1 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 1 diabetes

41. ABCD position statement on standards of care for management of adults with type 1 diabetes

ABCD position statement on standards of care for management of adults with type 1 diabetes Standards of Care for Management of Adults with Type 1 Diabetes | ABCD (Diabetes Care) Ltd You are here: Standards of Care for Management of Adults with Type 1 Diabetes 2020 ABCD Standards of care for the management of adults with type 1 diabetes provides comprehensive standards for units providing care to people with type 1 diabetes and is intended as a resource for specialist teams. A summary document (...) is also available which includes a short summary of the recommendations from each section. The sections on inpatient care and management of diabetic emergencies are particularly relevant today. We are grateful to all the contributors. Discipline: Diabetes Clinical taxonomy: Type 1 diabetes mellitus Resource taxonomy: Guidelines Position Paper Information for HCPs Follow Us Address for correspondence: ABCD (Diabetes Care) Ltd, Miria House, 1683b High Street, Knowle, Solihull, West Midlands, B93 0LL

2020 Association of British Clinical Diabetologists

42. Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study

: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2020 Apr 2. doi: 10.1111/dom.14041. Online ahead of print. Safety of Dapagliflozin in a Broad Population of Patients With Type 2 Diabetes: Analyses From the DECLARE-TIMI 58 Study , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Diabetes Unit, Department of Endocinology and Metabolism, Hadassah Medical Center, Hebrew University of Jerusalem (...) Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study Safety of Dapagliflozin in a Broad Population of Patients With Type 2 Diabetes: Analyses From the DECLARE-TIMI 58 Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National

2020 EvidenceUpdates

43. Obstructive Sleep Apnea, a Risk Factor for Cardiovascular and Microvascular Disease in Patients With Type 2 Diabetes: Findings From a Population-Based Cohort Study Full Text available with Trip Pro

Partners, Birmingham, U.K. 6 Midlands Health Data Research UK, Birmingham, U.K. PMID: 32345651 DOI: Item in Clipboard Obstructive Sleep Apnea, a Risk Factor for Cardiovascular and Microvascular Disease in Patients With Type 2 Diabetes: Findings From a Population-Based Cohort Study Nicola J Adderley et al. Diabetes Care . 2020 . Show details Diabetes Care Actions . 2020 Apr 28;dc192116. doi: 10.2337/dc19-2116. Online ahead of print. Authors , , , , , , , , , , Affiliations 1 Institute of Applied Health (...) care database from 1 January 2005 to 17 January 2018. Participants aged ≥16 years with type 2 diabetes were included. Exposed participants were those who developed OSA after their diabetes diagnosis; unexposed participants were those without diagnosed OSA. Outcomes were composite CVD (ischemic heart disease [IHD], stroke/transient ischemic attack [TIA], heart failure [HF]), peripheral vascular disease (PVD), atrial fibrillation (AF), peripheral neuropathy (PN), diabetes-related foot disease (DFD

2020 EvidenceUpdates

44. Screening and Treatment Outcomes in Adults and Children With Type 1 Diabetes and Asymptomatic Celiac Disease: The CD-DIET Study

Screening and Treatment Outcomes in Adults and Children With Type 1 Diabetes and Asymptomatic Celiac Disease: The CD-DIET Study Screening and Treatment Outcomes in Adults and Children With Type 1 Diabetes and Asymptomatic Celiac Disease: The CD-DIET Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health (...) Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Jul;43(7):1553-1556. doi: 10.2337/dc19-1944. Epub 2020 Apr 28. Screening and Treatment Outcomes in Adults and Children With Type 1 Diabetes and Asymptomatic Celiac Disease: The CD-DIET Study , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Division of Endocrinology, Department of Pediatrics, The Hospital

2020 EvidenceUpdates

45. Screening for type 2 diabetes mellitus. (Abstract)

Screening for type 2 diabetes mellitus. Diabetes mellitus, a metabolic disorder characterised by hyperglycaemia and associated with a heavy burden of microvascular and macrovascular complications, frequently remains undiagnosed. Screening of apparently healthy individuals may lead to early detection and treatment of type 2 diabetes mellitus and may prevent or delay the development of related complications.To assess the effects of screening for type 2 diabetes mellitus.We searched CENTRAL (...) % of participants were women; the average age of participants was 58.2 years in the screening group and 57.9 years in the no-screening group. Almost half of participants in both groups were on antihypertensive medication. The findings from the first phase of this study indicate that screening compared to no screening for type 2 diabetes did not show a clear difference in all-cause mortality (hazard ratio (HR) 1.06, 95% confidence interval (CI) 0.90 to 1.25, low-certainty evidence). Screening compared

2020 Cochrane

46. Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis. Full Text available with Trip Pro

Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis. To estimate and compare progression rates to type 2 diabetes mellitus (T2DM) in women with gestational diabetes mellitus (GDM) and healthy controls.Systematic review and meta-analysis.Medline and Embase between January 2000 and December 2019, studies published in English and conducted on humans.Observational studies investigating progression to T2DM. Inclusion criteria were (...) postpartum follow-up for at least 12 months, incident physician based diagnosis of diabetes, T2DM reported as a separate outcome rather than combined with impaired fasting glucose or impaired glucose tolerance, and studies with both a group of patients with GDM and a control group.This meta-analysis of 20 studies assessed a total of 1 332 373 individuals (67 956 women with GDM and 1 264 417 controls). Data were pooled by random effects meta-analysis models, and heterogeneity was assessed by use of the I2

2020 BMJ

47. Dulaglutide (Trulicity) and type 2 diabetes. No reduction in all-cause mortality or cardiovascular mortality

Dulaglutide (Trulicity) and type 2 diabetes. No reduction in all-cause mortality or cardiovascular mortality Prescrire IN ENGLISH - Spotlight '' Dulaglutide (Trulicity) and type 2 diabetes. No reduction in all-cause mortality or cardiovascular mortality'', 1 May 2020 {1} {1} {1} | | > > > Dulaglutide (Trulicity) and type 2 diabetes. No reduction in all-cause mortality or cardiovascular mortality Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |    (...) or cardiovascular mortality. Full text available for free download. Summary In a randomised, placebo-controlled trial i ncluding about 10 000 patients with type 2 diabetes and a mean HbA1c of 7.3% at enrolment, addition of dulaglutide to their usual hypoglycaemic therapy did not reduce all-cause or cardiovascular mortality after a follow-up of about 5 years. The increased risk of acute pancreatitis and pancreatic or thyroid cancer must be taken into account, as with any GLP-1 receptor agonist. Full text

2020 Prescrire

48. Association of Intensive Lifestyle Intervention, Fitness, and Body Mass Index With Risk of Heart Failure in Overweight or Obese Adults With Type 2 Diabetes Mellitus: An Analysis From the Look AHEAD Trial

With Type 2 Diabetes Mellitus: An Analysis From the Look AHEAD Trial Ambarish Pandey et al. Circulation . 2020 . Show details Circulation Actions . 2020 Apr 21;141(16):1295-1306. doi: 10.1161/CIRCULATIONAHA.119.044865. Epub 2020 Mar 5. Authors # , # , , , , , , , , , , Affiliations 1 Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas (A.P., K.V.P., D.K.M., J.D.B.). 2 Department of Biostatistics and Data Science (J.L.B., S.A.G.), Wake Forest (...) Association of Intensive Lifestyle Intervention, Fitness, and Body Mass Index With Risk of Heart Failure in Overweight or Obese Adults With Type 2 Diabetes Mellitus: An Analysis From the Look AHEAD Trial Association of Intensive Lifestyle Intervention, Fitness, and Body Mass Index With Risk of Heart Failure in Overweight or Obese Adults With Type 2 Diabetes Mellitus: An Analysis From the Look AHEAD Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage

2020 EvidenceUpdates

49. A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (Onset 9) Full Text available with Trip Pro

, in Adults With Type 2 Diabetes (Onset 9) , , , , , , , , , , Affiliations Expand Affiliations 1 Mountain Diabetes and Endocrine Centre, Asheville, NC mountaindiabetes@msn.com. 2 Novo Nordisk A/S, Søborg, Denmark. 3 Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Bundang Hospital, Seongnam, South Korea. 4 Novo Nordisk A/S, Aalborg, Denmark. 5 Santojanni Hospital and CENUDIAB, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina. 6 Institute (...) Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (Onset 9) Wendy S Lane et al. Diabetes Care . 2020 . Show details Diabetes Care Actions . 2020 Mar 24;dc192232. doi: 10.2337/dc19-2232. Online ahead of print. Authors , , , , , , , , , , Affiliations 1 Mountain Diabetes and Endocrine Centre, Asheville, NC mountaindiabetes@msn.com. 2 Novo Nordisk A/S

2020 EvidenceUpdates

50. Management of Hypoglycaemia in Children and Young People with Type 1 Diabetes

Management of Hypoglycaemia in Children and Young People with Type 1 Diabetes ssociation of Children’s Diabetes Clinicians Clinicians Version 4, May 2018 Review 2021 Authors: SM Ng, E Williams, F Ackland, C Burren, J Edge, E Hind, A McAulay, Bill Lamb 1 SETTING Children and young people with diabetes mellitus PATIENTS Children and young people with diabetes mellitus Guidance • Definition of hypoglycaemia in children with diabetes is a blood glucose 4.0mmol/L, Retest 20-30 minutes later (...) and caregivers, especially when there is a high risk of severe hypoglycaemia. Education on administration of glucagon is essential Blood glucose monitoring should be performed prior to exercise, and extra carbohydrates should be consumed based on the blood glucose level and the expected intensity and duration of the exercise REFERENCE 1. NICE (2015) Diabetes (type 1 and type 2) in children and young people. NICE guideline NG18 www.nice.org.uk/guidance/ng18 2. ISPAD Clinical Practice Consensus Guidelines 2014

2020 British Society for Paediatric Endocrinology and Diabetes

51. Care of the Well Child-Newly Diagnosed with Type 1 Diabetes

Care of the Well Child-Newly Diagnosed with Type 1 Diabetes Version 4, Dec 2019 Review 2022 Authors: J Chizo Agwu, SM Ng, A Timmis, C Moudiotis, K. Matyka,, N.P.Wright, M. Kershaw S.Bahl, A. Alston . N Trevelyan Page of 7 1 ssociation of Children’s Diabetes Clinicians Clinical Guideline Care of the well child, newly diagnosed with Type 1 Diabetes Mellitus SETTING Insert hospital name FOR STAFF Medical and nursing staff PATIENTS Children with diabetes and their families (...) to metabolic disturbance 12 . ? Antibody markers predicting type 1 diabetes: NICE advises against using Islet Cell Antibodies (ICA)and Glutamic Acid Decarboxylase Autoantibodies (GAD antibodies) to distinguish between Type 1 and other forms of diabetes, but they may be helpful as part of an overall clinical picture. o Antibody negative diabetes is not unusual. Reports suggest somewhere between 20 to 30% of children may be antibody negative at diagnosis 3,4 . Islet cell antibodies are more likely

2020 British Society for Paediatric Endocrinology and Diabetes

52. Metabolic surgery for the treatment of type 2 diabetes: A network meta-analysis of randomized controlled trials Full Text available with Trip Pro

Diabetes Obes Metab Actions . 2020 Apr 3. doi: 10.1111/dom.14045. Online ahead of print. Metabolic Surgery for the Treatment of Type 2 Diabetes: A Network Meta-Analysis of Randomized Controlled Trials , , , Affiliations Expand Affiliations 1 Diabetology, Careggi Hospital, Florence, Italy. 2 University of Florence, Florence, Italy. PMID: 32243058 DOI: Item in Clipboard Metabolic Surgery for the Treatment of Type 2 Diabetes: A Network Meta-Analysis of Randomized Controlled Trials Barbara Cresci et al (...) . Diabetes Obes Metab . 2020 . Show details Diabetes Obes Metab Actions . 2020 Apr 3. doi: 10.1111/dom.14045. Online ahead of print. Authors , , , Affiliations 1 Diabetology, Careggi Hospital, Florence, Italy. 2 University of Florence, Florence, Italy. PMID: 32243058 DOI: Item in Clipboard Full-text links Cite Abstract Aim: To compare different types of metabolic surgery (MS) with medical therapy (MT) for the treatment of type 2 diabetes (T2D). Materials and methods: We conducted a network-meta-analysis

2020 EvidenceUpdates

53. Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial Full Text available with Trip Pro

: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2020 Apr 3. doi: 10.1111/dom.14043. Online ahead of print. Differential Glycaemic Control With Basal Insulin Glargine 300 U/mL Versus Degludec 100 U/mL According to Kidney Function in Type 2 Diabetes: A Subanalysis From the BRIGHT Trial , , , , , , , , , Affiliations Expand Affiliations 1 Diabetes Centre, Institute for Clinical (...) School, Perugia, Italy. PMID: 32243043 DOI: Item in Clipboard Differential Glycaemic Control With Basal Insulin Glargine 300 U/mL Versus Degludec 100 U/mL According to Kidney Function in Type 2 Diabetes: A Subanalysis From the BRIGHT Trial Martin Haluzík et al. Diabetes Obes Metab . 2020 . Show details Diabetes Obes Metab Actions . 2020 Apr 3. doi: 10.1111/dom.14043. Online ahead of print. Authors , , , , , , , , , Affiliations 1 Diabetes Centre, Institute for Clinical and Experimental Medicine

2020 EvidenceUpdates

54. Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial Full Text available with Trip Pro

Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial (...) : ( ) Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Apr 15;dc192452. doi: 10.2337/dc19-2452. Online ahead of print. Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2

2020 EvidenceUpdates

55. Combined continuous glucose monitoring and subcutaneous insulin infusion versus self-monitoring of blood glucose with optimized multiple injections in people with type 1 diabetes: A randomized crossover trial Full Text available with Trip Pro

Combined continuous glucose monitoring and subcutaneous insulin infusion versus self-monitoring of blood glucose with optimized multiple injections in people with type 1 diabetes: A randomized crossover trial Combined Continuous Glucose Monitoring and Subcutaneous Insulin Infusion Versus Self-Monitoring of Blood Glucose With Optimized Multiple Injections in People With Type 1 Diabetes: A Randomized Crossover Trial - PubMed This site needs JavaScript to work properly. Please enable it to take (...) when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2020 Mar 12. doi: 10.1111/dom.14028. Online ahead of print. Combined Continuous Glucose Monitoring and Subcutaneous Insulin Infusion Versus Self-Monitoring of Blood Glucose With Optimized Multiple Injections in People With Type 1 Diabetes: A Randomized Crossover Trial

2020 EvidenceUpdates

56. Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes. (Abstract)

Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes. The restricted mean survival time (RMST) has been advocated as an alternative or a supplement to the hazard ratio for reporting the effect of an intervention in a randomized clinical trial. The RMST difference allows quantification of the postponement of an outcome during a specified (restricted) interval and corresponds to the difference between (...) the areas under the 2 survival curves for the intervention and control groups. This article presents examples of the use of the RMST in a research and a clinical context. First, the authors demonstrate how the RMST difference can answer research questions about the efficacy of different treatments. Estimates are presented for the effects of pharmacologic or strategy-driven glucose-lowering interventions for adults with type 2 diabetes from 36 trials and 9 follow-up studies reporting cardiovascular

2020 Annals of Internal Medicine

57. Insulin glargine/lixisenatide (Suliqua) - for the treatment of adults with type 2 diabetes mellitus

Insulin glargine/lixisenatide (Suliqua) - for the treatment of adults with type 2 diabetes mellitus 1 Published 13 April 2020 1 SMC2235 insulin glargine plus lixisenatide (Suliqua®), 100 units/mL plus 50 microgram/mL and 100 units/mL plus 33 micrograms/mL solution for subcutaneous injection in pre-filled pens Aventis Pharma Limited, trading as Sanofi 06 March 2020 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug (...) insulin. SMC restriction: for use in patients who are uncontrolled on basal insulin (glycosylated haemoglobin [HbA1c] > 7.5% [59mmol/mol]) and for whom a GLP-1 receptor agonist is appropriate as an add-on intensification therapy to basal insulin analogues. Insulin glargine/lixisenatide improved glycaemic control compared with insulin glargine alone in adults with inadequately controlled type 2 diabetes mellitus. Chairman Scottish Medicines Consortium www.scottishmedicines.org.uk 2 Indication

2020 Scottish Medicines Consortium

58. Insulin pumps for people with Type 1 Diabetes

Insulin pumps for people with Type 1 Diabetes 1 Driving better decision-making in healthcare Continuous subcutaneous insulin infusion therapy for treating type 1 diabetes Technology Guidance from the MOH Medical Technology Advisory Committee Published on 23 March 2020 Guidance recommendations The Ministry of Health Medical Technology Advisory Committee has recommended: ? Continuous subcutaneous insulin infusion therapy (CSII) and its consumables as a treatment option for adults and children (...) with type 1 diabetes mellitus: o who use multiple daily injections of insulin (MDI) to achieve target HbA1c but result in the person experiencing disabling hypoglycaemia, where disabling hypoglycaemia is defined as the repeated and unpredictable occurrence of hypoglycaemia that results in persistent anxiety about recurrence and is associated with a significant adverse effect on quality of life (QoL); or o who have unacceptably high HbA1c (i.e. at 8.5% or above) on MDI despite a high level of care, where

2020 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

59. Early Childhood Antibiotic Treatment for Otitis Media and Other Respiratory Tract Infections Is Associated With Risk of Type 1 Diabetes: A Nationwide Register-Based Study With Sibling Analysis Full Text available with Trip Pro

Early Childhood Antibiotic Treatment for Otitis Media and Other Respiratory Tract Infections Is Associated With Risk of Type 1 Diabetes: A Nationwide Register-Based Study With Sibling Analysis Early Childhood Antibiotic Treatment for Otitis Media and Other Respiratory Tract Infections Is Associated With Risk of Type 1 Diabetes: A Nationwide Register-Based Study With Sibling Analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set (...) : Send at most: Send even when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Mar 4;dc191162. doi: 10.2337/dc19-1162. Online ahead of print. Early Childhood Antibiotic Treatment for Otitis Media and Other Respiratory Tract Infections Is Associated With Risk of Type 1 Diabetes: A Nationwide Register-Based Study With Sibling Analysis

2020 EvidenceUpdates

60. Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial. Bromodomain and extraterminal proteins are epigenetic regulators of gene transcription. Apabetalone is a selective bromodomain and extraterminal protein inhibitor targeting bromodomain 2 and is hypothesized to have potentially favorable effects on pathways related to atherothrombosis. Pooled phase 2 data suggest (...) favorable effects on clinical outcomes.To test whether apabetalone significantly reduces major adverse cardiovascular events.A randomized, double-blind, placebo-controlled trial, conducted at 190 sites in 13 countries. Patients with an acute coronary syndrome in the preceding 7 to 90 days, type 2 diabetes, and low high-density lipoprotein cholesterol levels were eligible for enrollment, which started November 11, 2015, and ended July 4, 2018, with end of follow-up on July 3, 2019.Patients were

2020 JAMA